Drug Interactions with CYP3A4

Introduction to CYP3A4

CYP3A4 is responsible for metabolizing 30-50% of all drugs currently available, and drug interactions involving CYP3A can be categorized as inhibition, induction, or substrate competition 1, 2

Cyclosporine is extensively metabolized by CYP3A4, according to the American Thoracic Society 3
Tacrolimus is extensively metabolized by hepatic and intestinal CYP3A4, as stated by the American Heart Association 4

Simvastatin and Lovastatin are administered as inactive lactone prodrugs and are avidly metabolized by CYP3A4, as reported by the Infectious Diseases Society of America 5
Atorvastatin is administered as an active hydroxy-acid form, but is still metabolized by CYP3A4, according to the American Heart Association 4
Pravastatin is eliminated by multiple pathways, particularly glucuronidation, as stated by the Infectious Diseases Society of America 5
Fluvastatin primarily uses CYP2C9 for metabolism, as reported by the Infectious Diseases Society of America 5

The use of CYP3A4 inhibitors with CYP3A4-metabolized statins can increase the risk of rhabdomyolysis, according to the American Heart Association 4
The use of CYP3A4 inducers can decrease immunosuppressant levels, increasing the risk of transplant rejection, as stated by the American Thoracic Society 3
Contraindicated combinations include aprepitant with pimozide, terfenadine, astemizole, or cisapride, and clarithromycin with pimozide, terfenadine, astemizole, cisapride, or ergot alkaloids, as recommended by the National Comprehensive Cancer Network 1, 6, 7
High-risk combinations, such as aprepitant with chemotherapeutic agents metabolized by CYP3A4, require significant dose adjustment or close monitoring, as recommended by the National Comprehensive Cancer Network 1, 6

The National Comprehensive Cancer Network recommends reducing substrate dose when adding a CYP3A inhibitor, and monitoring for toxicity or reduced efficacy 1, 6
The American Heart Association recommends monitoring INR more frequently, especially during the first week of co-administration, when warfarin is used with CYP3A inhibitors 1, 8
For direct oral anticoagulants, apixaban dose should be reduced by 50% when used with strong CYP3A4 and P-gp inhibitors, and strong CYP3A inducers should be avoided with all DOACs, as recommended by the American Heart Association 8, 9
Therapeutic drug monitoring is recommended for narrow therapeutic index drugs when CYP3A inhibitors or inducers are added or removed, as recommended by the National Comprehensive Cancer Network 1, 6
Clinical monitoring for signs of toxicity, laboratory monitoring, and ECG monitoring are also recommended when combining multiple medications, as recommended by the American Heart Association 8, 10

When using docetaxel, paclitaxel, etoposide, or irinotecan with CYP3A inhibitors, consider dose reduction and monitor closely for toxicity, as recommended by the National Comprehensive Cancer Network 1, 6
When using TKIs with lopinavir/ritonavir, avoid combination or reduce TKI dose and monitor for adverse events, as recommended by the National Comprehensive Cancer Network 10
When using clarithromycin with CYP3A substrates, consider alternative macrolide with less CYP3A inhibition potential or adjust substrate dose, as recommended by the National Comprehensive Cancer Network 7

The American Heart Association recommends considering patient variability, polypharmacy, and additive toxicities when managing CYP3A interactions 8, 10